The Ratio KL-6 to SLX in Serum for Prediction of the Occurrence of Drug-Induced Interstitial Lung Disease in Lung Cancer Patients with Idiopathic Interstitial Pneumonias Receiving Chemotherapy

Kashiwabara, Kosuke; Semba, Hiroshi; Fujii, Shigehiko; Tsumura, Shinsuke; Aoki, Ryota

doi:10.3109/07357907.2015.1069832

Cited by 7 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The bene t of chemotherapy in SCLC patients with ILD is considerably high compared with NSCLC, even when the risk of AE is taken into account, as SCLC has a poor prognosis and a high response rate to anti-cancer agents. [19] In a previous study, Minegishi et al [20] prospectively analyzed the safety and e cacy of chemotherapy for patients with SCLC and ILD, whereas studies of chemotherapy for patients with lung cancer and ILD are limited to retrospective analyses of a small number of cases. These studies revealed that chemotherapy using a platinum agent and etoposide might help to improve prognosis, although the incidence of AE is approximately 2-16%, and the prognosis is relatively poor compared to that in cases without ILD.…”

Section: Discussionmentioning

confidence: 99%

Prognostic impact of interstitial lung disease on pulmonary high-grade neuroendocrine carcinoma

Sakai,

Azuma,

Kusano

et al. 2024

Preprint

View full text Add to dashboard Cite

Pulmonary high-grade neuroendocrine carcinomas (HGNECs) have poor prognoses and require multimodal treatment, and interstitial lung disease (ILD) restricts sufficient treatment of patients with lung cancer. We aimed to clarify ILD’s prognostic impact on pulmonary HGNEC, which has previously gone unreported. We retrospectively analyzed 53 patients with HGNEC who underwent resections at our department between 2006 and 2021 and evaluated the clinicopathological prognostic features, including ILD. The patients’ mean age was 70 years; 46 (87%) were male, and all were smokers. Large-cell neuroendocrine and small-cell lung carcinomas were diagnosed in 36 (68%) and 17 (32%) patients, respectively. The pathological stages were stage I, II, and III in 31 (58%), 11 (21%), and 11 (21%) patients, respectively. Nine patients (17%) had ILD, a significant overall survival prognostic factor in a multivariate Cox proportional hazards regression analysis (p = 0.032), along with non-administration of platinum-based adjuvant chemotherapy (p = 0.002), non-receival of adjuvant chemotherapy, and adverse event development. The 5-year survival rate of the ILD patients was 0%, significantly worse than that of patients without ILD (58.7%; p = 0.003). Patients with HGNEC and ILD had a poor prognosis owing to adjuvant therapy’s limited availability for recurrence and the development of AEs associated with ILD.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic impact of interstitial lung disease on pulmonary high-grade neuroendocrine carcinoma

Sakai,

Azuma,

Kusano

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Few reports describe other serum biomarkers for D-ILD, except for KL-6, SP-A, and SP-D. Serum KL-6 to serum sialyl lewis X-I antigen ratio (K/S ratio) has been reported to be a useful predictive marker for D-ILD in patients with lung cancer and ILD [ 18 ]. In this report, high K/S ratio (> 20), which was determined before the first-line chemotherapy, tended to increase the risk of D-ILD.…”

Section: Discussionmentioning

confidence: 99%

Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study

et al. 2017

View full text Add to dashboard Cite

BackgroundInterstitial lung diseases induced by anticancer agents (ILD-AA) are rare adverse effects of anticancer therapy. However, prognostic biomarkers for ILD-AA have not been identified in patients with advanced lung cancer. Our aim was to analyze the association between serum biomarkers sialylated carbohydrate antigen Krebs von den Lungen-6 (KL-6) and surfactant protein D (SP-D), and clinical characteristics in patients diagnosed with ILD-AA.MethodsBetween April 2011 and March 2016, 1224 advanced lung cancer patients received cytotoxic agents and epidermal growth factor receptor tyrosine kinase inhibitors at Juntendo University Hospital and Juntendo University Urayasu Hospital. Of these patients, those diagnosed with ILD-AA were enrolled in this case control study. ΔKL-6 and ΔSP-D were defined as the difference between the levels at the onset of ILD-AA and their respective levels prior to development of ILD-AA. We evaluated KL-6 and SP-D at the onset of ILD-AA, ΔKL-6 and ΔSP-D, the risk factors for death related to ILD-AA, the chest high resolution computed tomography (HRCT) findings, and survival time in patients diagnosed with ILD-AA.ResultsThirty-six patients diagnosed with ILD-AA were enrolled in this study. Among them, 14 patients died of ILD-AA. ΔSP-D in the patients who died was significantly higher than that in the patients who survived. However, ΔKL-6 did not differ significantly between the two groups. Moreover, ΔSP-D in patients who exhibited diffuse alveolar damage was significantly higher than that in the other patterns on HRCT. Receiver operating characteristic curve analysis was used to set the optimal cut off value for ΔSP-D at 398 ng/mL. Survival time for patients with high ΔSP-D (≥ 398 ng/mL) was significantly shorter than that for patients with low ΔSP-D. Multivariate analysis revealed that ΔSP-D was a significant prognostic factor of ILD-AA.ConclusionsThis is the first research to evaluate high ΔSP-D (≥ 398 ng/mL) in patients with ILD-AA and to determine the risk factors for ILD-AA in advanced lung cancer patients. ΔSP-D might be a serum prognostic biomarker of ILD-AA. Clinicians should evaluate serum SP-D during chemotherapy and should carefully monitor the clinical course in patients with high ΔSP-D.

show abstract

“…SCLC is less common as NSCLC in patients with ILDs, accounting for approximately 20% of lung cancers [158]. Most reports suggest that the presence of ILD, and particularly of IPF, is associated with reduced overall survival [159][160][161][162]. Individuals diagnosed with SCLC and ILD exhibit similar responses to standard treatment to the general population, provided they tolerate chemotherapy [159,160,163].…”

Section: Treatment Options For Sclc Patients With Ildmentioning

confidence: 99%

Lung Cancer and Interstitial Lung Diseases

Drakopanagiotakis,

Krauss,

Michailidou

et al. 2024

Preprint

View full text Add to dashboard Cite

Lung cancer remains one of the leading causes of cancer-related mortality worldwide. There is evidence of a complex interplay between lung cancer and interstitial lung disease (ILD), affecting disease progression, management strategies, and patient outcomes. Both conditions develop as the result of common risk factors such as smoking, environmental exposures, and genetic predispositions. The presence of ILD poses diagnostic and therapeutic challenges in lung cancer management, including difficulties in interpreting radiological findings, increased susceptibility to treatment-related toxicities, such as acute exacerbation of ILD after surgery and pneumonitis after radiation therapy and immunotherapy. Moreover, due to the lack of large, phase III randomized controlled trials in patients with lung cancer and ILDs, the evidence-based therapeutic options remain limited. The role of antifibrotic treatment in the prevention of lung-cancer-related treatment toxicities remains to be elucidated. Emerging diagnostic modalities and biomarkers, and optimizing personalized treatment strategies are essential to improve outcomes in this patient population.

show abstract

The Ratio KL-6 to SLX in Serum for Prediction of the Occurrence of Drug-Induced Interstitial Lung Disease in Lung Cancer Patients with Idiopathic Interstitial Pneumonias Receiving Chemotherapy

Cited by 7 publications

References 23 publications

Prognostic impact of interstitial lung disease on pulmonary high-grade neuroendocrine carcinoma

Prognostic impact of interstitial lung disease on pulmonary high-grade neuroendocrine carcinoma

Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study

Lung Cancer and Interstitial Lung Diseases

Contact Info

Product

Resources

About